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INJECTING CAUTION: A NEED FOR ENHANCED
STATE-LEVEL ENFORCEMENT TACTICS
TARGETING THE COSMETIC USE OF LIQUID
SILICONE PRODUCTS
Katherine Cohen Cooper*
INTRODUCTION
Liquid silicone, first developed commercially for the purposes of
insulating electrical transformers, gained popularity in the United States
during the second half of the twentieth century as a cosmetic injection.1
Although the United States Food and Drug Administration (“FDA”) has
never approved liquid silicone for cosmetic uses, physicians have injected
the substance in patients’ breasts, bodies, and faces for cosmetic
enhancement since the 1950s.2 In more recent years, as record numbers of
patients seek out minimally invasive cosmetic procedures such as
injectables, illicit liquid silicone injections have been on the rise.3 Often,
patients hoping to obtain quick cosmetic results turn to unlicensed
professionals to administer liquid silicone injections, or receive injections of
adulterated or industrial-grade silicone.4 While these cosmetic interventions
can be easy to obtain and cost thousands of dollars less than a similar
procedure performed by a licensed physician, these conveniences all too
frequently come at the expense of patient health and safety.5
The following article provides a background of the development of liquid
silicone as a tool for cosmetic enhancement, as well as a brief overview of

	
  
* J.D., Harvard Law School, 2013; B.A., Duke University, 2007.
1. Philip Hilts, Strange History of Silicone Held Many Warning Signs, N.Y. TIMES,
Jan. 18, 1992, http://www.nytimes.com/1992/01/18/us/strange-history-of-silicone-heldmany-warning-signs.html?pagewanted=all&src=pm.
2. Judy Foreman, Women and Silicone: A History of Risk, BOS. GLOBE, Jan. 19,
1992, at 1.
3. Amanda Gardner, Illegal Silicone Buttock Injections Can Be Deadly, Experts
Say, USA TODAY (Oct. 28, 2011, 2:42 PM), http://usatoday30.usatoday.com/new/health/
story/health/story/2011-10-29/illegal-silicone-buttock-injections-can-be-deadly-expertssay/50978858/1.
4. Angela Esther Kim, “Wine, Cheese and a Dash of Poison in the Forehead:”
Exploring the Evolution of the Injectable Filler Industry and the Consequent Implications
for Regulatory Action, at 29 (May 19, 2006) (unpublished 3L student course paper,
Harvard Law School) (on file with Digital Access to Scholarship at Harvard), available
at: http://dash.harvard.edu/bitstream/handle/1/9414576/KimA06.html?sequence=2.
5. Id. at 29-30.
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the historical regulatory approach toward controlling cosmetic uses of these
products. The article goes on to describe the current legal status of liquid
silicone injections, as well as the scope of its current uses. It also examines
various legal and regulatory mechanisms that have been offered as means to
control illicit uses of liquid silicone injections. Given the barriers towards
achieving effective federal regulation and control of illicit liquid silicone
injections, as evidenced through descriptions of the current and historical
regulatory regimes, this article concludes that state-level regulation and
enforcement will be the most practical route for controlling unsafe and
illegal cosmetic liquid silicone procedures. As such, this article advocates
for a selection of promising state-level legal reforms targeting both
physicians and unlicensed individuals that seek to provide patients with
injections of liquid silicone.
I. THE DEVELOPMENT OF LIQUID SILICONE INJECTIONS
The scientific term for liquid silicone is dimethylpolysiloxane fluid.6 The
silicones are a family of chemically related substances comprised of silicon
atoms bonded to oxygen and carbon atoms; silicone polymers range in
viscosity from fluids to solids.7 Although the term “silicone” has become
synonymous with cosmetic uses, the substance was first developed for
industrial purposes. During World War II, the United States military used
liquid silicone to insulate electrical transformers.8 Also during this era,
however, U.S. troops stationed in Japan began to notice that drums of
transformer insulating fluid were being stolen from docks in Japanese
harbors. It became evident that this silicone fluid was being injected into the
breasts of Asian prostitutes who sought a more Western appearance to cater
to the American servicemen.9 Silicone breast injections migrated to
America in the 1950s when Asians who practiced the procedure immigrated.
Initially, silicone breast injections were black market procedures, most
commonly administered to women who worked in the entertainment
industry.10 During the 1950s and early 1960s, transformer fluid made by
Dow Corning (“Dow”) was the only liquid silicone product on the market;

	
  
6. Rhoda S. Narins & Kenneth Beer, Liquid Injectable Silicone: A Review of Its
History, Immunology, Technical Considerations, Complications, and Potential, 118
PLASTIC & RECONSTRUCTIVE SURGERY J. 77S, 78S (2006).
7. R.R. LeVier, M.C. Harrison, R.R. Cook, & T.H. Lane, What is Silicone?, 92
PLASTIC & RECONSTRUCTIVE SURGERY J. 163 (Jul. 1993); see also M. Sharon Webb,
Cleopatra’s Needle: The History and Legacy of Silicone Injections, 2 (Jan. 1997)
(unpublished course paper) (on file with Harvard Law School).
8. Hilts, supra, note 1.
9. Id.
10. Foreman, supra note 2.
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thus, throughout this time period, only this industrial-grade material was
used in these cosmetic procedures.11
As time passed, liquid silicone injections became more mainstream. One
physician in Las Vegas was quoted in a 1963 Newsweek article claiming to
have injected 16,000 doses of silicone into the breasts of over 200 women.12
As the popularity of silicone injections grew, reports of adverse events
associated with these procedures also became more prevalent. For example,
clinicians began to note that liquid silicone injected in the breasts tended to
migrate to adjacent areas and form irregular subcutaneous masses.13 To
address this issue, a Beverly Hills physician named Dr. Sakurai popularized
a version of the liquid silicone formula that contained inflammatory agents.14
These new agents produced scarring around the injection area, and when
added to the liquid silicone, helped the silicone fluid to remain immobilized
in the desired region.15 Because these adulterants caused separate problems
in patients, Dow developed and marketed a medical grade liquid silicone,
intended for use in clinical experimentation.16
In large part, Dow developed medical grade silicone because the company
had become aware that physicians were putting liquid silicone to wide use.
Capitalizing on the market potential of medical uses for liquid silicone, Dow
established a medical products business division in 1962.17 Along with this
new endeavor came oversight from the FDA. As Dow assumed its new role
as a medical products company, the company instituted efforts to avoid
misuse of medical grade liquid silicone by its customers. Purchasers of its
Medical 360 fluid were required to sign an affidavit stating that the material
would only be used for lubrication purposes.18 Despite this effort, however,

	
  
11. E. L. WARRICK, FORTY YEARS OF FIRSTS 169 (1990).
12. Paul E. Chasan, The History of Injectable Silicone Fluids for Soft Tissue
Augmentation, 120 PLASTIC & RECONSTRUCTIVE SURGERY J. 7, 2034, 2035 (Dec. 2007);
see also Webb, supra note 7, at 11.
13. See, e.g., N. Ben-Hur, D.L. Ballantyne, T.D. Rees, & I. Seidman, Local and
Systemic Effects of Dimethylpolysiloxane Fluid in Mice, 39 PLASTIC & RECONSTRUCTIVE
SURGERY J. 423 (1967).
14. Chasan, supra note 12, at 2035.
15. Is the FDA Protecting Patients from the Dangers of Silicone Breast Implants?:
Hearing before the Human Resources and Intergovernmental Relations Subcommittee of
the Committee on Government Operations, 101st Cong. 30 (Dec. 18 1990) (statement of
Norman D. Anderson, M.D., Associate Professor of Medicine and Surgery, Johns
Hopkins University School of Medicine, and Former Chairman, General and Plastic
Surgery Devices Advisory Panel, FDA).
16. F. McDowell, Complications with Silicone: What Grade of Silicone? How Do
We Know it Was Silicone?, 61 PLASTIC & RECONSTRUCTIVE SURGERY J. 892 (June 1978).
17. DOW CORNING CORP., HIGHLIGHTS FROM THE HISTORY OF DOW CORNING
CORPORATION, SILICONE PIONEER, http://www.dowcorning.com/content/publishedlit/014027-01.pdf.
18. See Webb, supra note 7, at 16-18.
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the FDA declared Medical 360 fluid to be a new drug in 1964, requiring the
substance to adhere to the Food, Drug and Cosmetic Act (“FDCA”) and
submit a successful New Drug Application (“NDA”).19
II. HISTORICAL REGULATION OF MEDICAL-GRADE LIQUID SILICONE
A. FDA Initially Classifies Liquid Silicone as a “Drug”
In response to the FDA’s classification of Medical 360 fluid as a drug,
Dow assembled a panel of scientific experts to begin conducting animal
studies involving liquid silicone. These experts were quickly convinced of
liquid silicone’s safety, and began to test the fluid in human patients.20 The
FDA permitted Dow to begin Phase II human subject trials in 1965, but
these studies were replete with design flaws.21 Having failed to amass
sufficient safety and effectiveness data by 1976, Dow withdrew the Medical
360 NDA and deferred its attempt to gain FDA approval for its liquid
silicone product. In 1977, Dow submitted an amended protocol for clinical
trials of Medical 360 fluid.22 Noting that Dow’s animal studies had been
plagued with inconsistencies, the FDA explicitly required that liquid silicone
trials only be used for serious facial deformities; cosmetic applications were
not allowed as part of these new clinical trial protocols.23 As a result,
responsibility for liquid silicone as a transitional medical device was given
to the Bureau of Devices and given a new investigational device exemption
number (“IDE”).24
B. Liquid Silicone is Re-Classified as a “Device” But Does Not Receive PreMarket Approval
As these renewed clinical trials were underway, the 1976 Medical Device
Amendments to the FDCA went into effect. These amendments charged the
FDA with identifying drugs that should be re-classified as devices; silicone

	
  
19. Id.
20. F.L. Ashley, S. Braley, & E.G. McNall, The Current Status of Silicone Injection
Therapy, 51 SURGICAL CLINICS N. AM. 501 (1971).
21. Id. Particularly troubling, it was found that silicone fluid tended to disappear
from the injection site. However, none of the researchers could determine where this
silicone had migrated.
22. Chasan, supra note 12.
23. See Promotion of Drugs and Medical Devices for Unapproved uses: Hearing
before the H. Comm. of Human Res. and Intergovernmental Relations Subcomm. of the
Comm. on Gov’t Operations, 102nd Cong., (207-208) (June 11, 1991) (Memorandum
from Paul F. Tilton to The Record, September 10 , 1990).
24. Id. at 208.
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injections were deemed a device in 1977.25 Subsequently, Dow researchers
continued clinical trials of silicone injections in patients with severe
deformities as investigational medical device trials.26 In 1988, the FDA
ruled that silicone injections should be considered Class III medical devices,
requiring that the devices obtain pre-market approval (“PMA”) from the
agency.27 As Dow gathered data for the PMA application, the FDA
requested an interim report, which the company filed in 1990. The agency
deemed the submitted material unsatisfactory, citing the dearth of long-term
follow-up with study patients, insufficient pre- and post-treatment lab
studies, no objective measures of improvement, and inadequate
demonstrations of individual patient results.28 Dow did not correct these
deficiencies in its data, nor did it file a formal PMA application or submit
further safety and efficacy information. Thus, the IDE that had allowed
Dow to continue clinical trials of the Medical 360 device permanently
expired in January 1992; the product was subsequently retired from clinical
medicine.29
C. Despite Lack of Pre-Market Approval, FDA Enforcement Against
Cosmetic Silicone Injections Is Weak
By 1992, the FDA had never approved liquid silicone injections as either
a drug or device.30 Nevertheless, silicone fluid was widely used within the
United States medical community at this time.31 Particularly popular was
the use of liquid silicone to cosmetically shape the face.32 While the FDA
occasionally issued rulings reflecting its approbation of silicone injections,
the agency generally exhibited ambivalence towards regulating liquid
silicone.33 For example, the FDA became aware that Dr. Norman
Orentreich, one of the investigators permitted to conduct liquid silicone trials
under Dow’s Medical 360 IDE, was injecting silicone fluid into patients for
reasons outside the scope of addressing serious facial deformities, as was

	
  
25. JUDITH JOHNSON, CONG. RESEARCH SERV., FDA REGULATION OF MEDICAL
DEVICES 5 (June 25, 2012).
26. See Webb, supra note 7, at 29.
27. Regulatory History of Breast Implants in the U.S., FOOD & DRUG ADMIN.,
http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/ImplantsandProsthe
tics/BreastImplants/ucm064461.htm (last visited May 12, 2014).
28. See Webb, supra note 7, at 30.
29. See id. at 31.
30. Webb, supra note 7, at 30 (stating that the IDE for silicone injections “became
invalid in January, 1992”).
31. Kim, supra note 4, at 25.
32. Id. at 24.
33. HR. REP. NO. 102-1064, at 3 (1992).
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specified in the IDE protocol.34 While the FDA did respond by dropping
Orentreich from the roster of approved investigators, he nevertheless
continued to maintain “a robust cosmetic practice as a dermatologist in New
York City, with appreciative movie stars as patients.”35 In the face of this
defiance, the FDA warned Orentreich about his continued cosmetic usage of
liquid silicone and called for an injunction in 1985.36 Ultimately, however,
Orentreich was permitted to continue his practice, and the injunction
recommendation was placed in permanent abeyance.37 As justification for
this inaction, the agency noted its reluctance “to single out one physician
when illegal use of liquid silicone was widespread,” and further that issues
related to the practice of medicine were best addressed at the state level.38
As cosmetic use of liquid silicone became increasingly widespread without
firm regulatory guidance from FDA, the Department of Justice stepped in
and began filing injunctions on behalf of the agency to prohibit physicians
from injecting silicone fluid in patients.39 In the early 1990s, the
Department of Justice filed its own injunction against Dr. Orentreich.40 By
1992, the FDA had followed suit, entering consent decrees of permanent
injunction against several additional physicians.41
D. States Attempt to Regulate Liquid Silicone in the Face of FDA Inaction
Although the FDA’s efforts to curb illegal silicone injections were limited
between 1964 and 1992, many states were more active in combating such
activity during this timeframe.42 As data in the medical literature and in
clinical practice regarding adverse effects of liquid silicone injections began
to accumulate, so too did political attention throughout many regions of the
country.43 In Nevada, a Las Vegas plastic surgeon alerted the state’s
attorney general to the dangers of these procedures and the health risks it
caused for the city’s entertainers.44 In 1975, Nevada passed a law
criminalizing silicone injections.45 States such as California soon followed

	
  
34. Webb, supra note 7, at 32.
35. Id. 32-33.
36. Id. at 34.
37. Id.
38. Id. at 33.
39. Press Release, Food and Drug Admin., Physicians to Stop Injecting Silicone for
Cosmetic
Treatment
of
Wrinkles
(Feb.
28,
1992),
available
at
http://www3.scienceblog.com/community/older/archives/M/1/fda0893.htm.
40. Kim, supra note 4, at 24.
41. Judith E. Foulke, Two Doctors Ordered to Stop Silicone Injections, FDA
CONSUMER, Mar. 1993, at 27.
42. Webb, supra note 7, at 23-24.
43. Id. at 24.
44. Foreman, supra note 2.
45. Id.
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suit, beginning to prosecute doctors for violating these laws.46 Medical
malpractice suits and criminal cases brought in state courts were also
successfully used to punish and hold responsible physicians and other
individuals who harmed patients with liquid silicone injections. In People v.
Ellison, for example, the defendant was convicted of involuntary
manslaughter for recklessly injecting silicone into a transgender woman.47
The principal factual issue at trial was whether the silicone injection caused
the victim’s death.48 On appeal, the court held that the victim’s death was
caused by the silicone injection because expert testimony concluded that the
cause of death was suffocation resulting from the presence of silicone
vacuoles in the victim’s lungs.49
III. CURRENT LEGAL AND REGULATORY STATUS OF LIQUID SILICONE
A. FDA Approval of Medical Devices Generally
Under Section 513(a) of the FDCA, the FDA determines whether
Premarket Approval (“PMA”) applications provide a “reasonable assurance
of [a device’s] safety and effectiveness” by “weighing any probable benefit
to health from the use of the device against any probable risk of injury or
illness from such use.”50 To aid in this process, PMA applicants submit
valid scientific evidence, including one or more clinical investigations where
appropriate, which FDA reviews to determine whether the device will have
the effect it purports or is represented to have under the conditions of use
prescribed, recommended, or suggested in the labeling of the device.51
Medical devices can be evaluated using clinical and non-clinical testing
methods.52 FDA assesses information provided in a PMA application
concerning the extent of probable benefits of the device by taking into
account factors such as the types of benefits involved, the magnitude of the
benefits, the probability of the patient experiencing one or more benefits,
and the duration of the effects.53 These benefits are balanced against the

	
  
46. NEV. REV. STAT. § 202.248 (1995); CAL. BUS. & PROF. CODE § 2251 (West
1980); see also Nelson v. Gault, 125 Cal. App. 3d 623, 639-40 (Cal. Ct. App. 1981)
(holding that physician’s testimony that he was aware that silicone was considered illegal
and that he was arrested for injecting it without a permit was admissible to prove
knowledge of the falsity of the representation made to patient that silicone was inert and
harmless).
47. People v. Ellison, 100 Ill. App. 3d 282, 283 (1981).
48. Id.
49. Id. at 290.
50. 21 U.S.C. § 360(a)(2)(C) (2010).
51. Id.
52. Id.
53. Id.
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probable risks and harms associated with the device, including the severity
and rates of harmful events associated with the use of the device, the
probability of a harmful event, and the duration of a harmful event.54
Additionally, FDA will consider factors such as uncertainty, characterization
of the condition, patient tolerance for risk, availability of alternative
treatments, and novelty of the technology in conducting a benefit-risk
determination.55
In the context of FDA approval for cosmetic or anti-aging devices,
measuring efficacy and comparing risks and benefits can be complicated.56
As an initial matter, “it is unclear what endpoints the [FDA] should require
manufacturers to use in order to prove efficacy.57 Additionally, it may be
difficult to identify the “symptoms” associated with aging or with cosmetic
problems, as well as to determine what qualifies as relief of those
“symptoms.”58 Nevertheless, FDA does approve many drugs and devices
for cosmetic indications, such as nonprescription contact lenses, breast
implants, and Botox.59 For example, in seeking approval of Botox cosmetic,
Allergan, the product’s manufacturer, conducted studies with co-primary
efficacy endpoints of the Investigator’s rating of glabellar line severity at
maximum frown at Day 30 after injection and the Subject’s Global
Assessment of change in appearance in glabellar lines at Day 30 after
injection.60 By the primary efficacy endpoint day, Day 30, 80% of subjects
had achieved a severity score of none or mild at maximum frown by the
investigator’s assessment, compared to 3% of placebo treated patients.61 On
the other hand, the most frequently reported adverse events following
injection of Botox Cosmetic were relatively minor, including headache,

	
  
54.
Id.
55. See FOOD & DRUG ADMIN., U.S. DEP’T OF HEALTH & HUM. SERVS., GUIDANCE
FOR INDUSTRY AND FOOD AND DRUG ADMINISTRATION STAFF: FACTORS TO CONSIDER
WHEN MAKING BENEFIT-RISK DETERMINATIONS IN MEDICAL DEVICE PREMARKET
APPROVAL AND DE NOVO CLASSIFICATIONS (Mar. 28, 2012), http://www.fda.gov/
downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM2
96379.pdf.
56. Maxwell J. Mehlman, et al., Anti-Aging Medicine: Can Consumers be Better
Protected?, 44 GERONTOLOGIST 304, 306 (2004).
57. Id.
58. Id.
59. Id. at 307.
60. FOOD & DRUG ADMIN, U.S. DEP’T OF HEALTH & HUM. SERVS., APPROVAL
RECOMMENDATION FOR STN 100300/5000 SUBMITTED BY ALLERGAN, INC. TO USE
BOTULINUM TOXIN TYPE A (BOTOX COSMETIC) FOR TREATMENT OF GLABELLAR FACIAL
LINES (Apr. 12, 2002), http://www.fda.gov/downloads/Drugs/ DevelopmentApproval
Process/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologi
cApplications/ucm088280.pdf [hereinafter FDA, BOTOX COSMETIC APPROVAL].
61. Id.

2014]

Injecting Caution

257

respiratory infection, flu, and nausea.62 Based on an analysis of these
results, the FDA approved Botox Cosmetic for the temporary reduction in
the appearance of moderate to severe glabellar lines in 2002.63
B. Legal “Off-Label” Uses of Approved Liquid Silicone Products
While liquid silicone has never received FDA approval for cosmetic use,
certain liquid silicone products were approved by the agency as medical
devices between 1994 and 1997. Section 201(h) of the FDCA defines
“device” as follows:
The term “device” . . . means an instrument, apparatus, implement,
machine, contrivance, implant, in vitro reagent, or other similar or
related article, including any component, part, or accessory, which
is . . . intended for use in the diagnosis of disease or other
conditions, or in the cure, mitigation, treatment, or prevention of
disease, in man or other animals, or intended to affect the structure
or any function of the body of man or other animals, and which
does not achieve its primary intended purposes through chemical
action within or on the body of man or other animals and which is
not dependent upon being metabolized for the achievement of its
primary intended purposes.64
Presently two liquid silicone devices have received pre-market approval
from the FDA: Adatosil 5000 and Silikon 1000; these devices are approved
for the treatment of complicated retinal detachments.65 Pursuant to this
approved indication, these liquid silicone products are temporarily injected
into the eye to hold the retina in place while it heals.66 FDA approval of
these liquid silicone products has opened the door for the legal
administration of liquid silicone injections for cosmetic treatment. This
legal but unapproved indication is known as an “off-label use.”67

	
  
62. Id.
63. Id.
64. 21 U.S.C. §321(h) (2010). It is important to note that the definition of a medical
device includes any article that is “intended to affect the structure or any function of the
body.” Therefore, a product intended for cosmetic use and designed to beautify or
promote attractiveness can nevertheless be classified as a medical device by the FDA,
regardless of whether the device is intended to be used for reconstructive or solely
cosmetic purposes.
65. Erin Gilbert, Andrea Hui, & Heidi A. Waldorf, The Basic Science of Dermal
Fillers: Past and Present: Part I: Background and Mechanisms of Action, 11 J. DRUGS
DERMATOLOGY 1064 (2012).
66. Vitreoretinal Surgery: ADATO Sil-O-Silicone Oil, BAUSCH & LOMB,
http://www.bausch.com/en/ECP/Our-Products/Vitreoretinal-Surgery/ADATO-Sil-OlSilicone-Oil (last visited Apr. 10, 2013).
67. “Off-label” and Investigational Use of Marketed Drugs, Biologics, and Medical
Devices–Information
Sheet,
FOOD
&
DRUG
ADMIN.,
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FDA defines off-label use as use for an “indication, dosage, form, dose
regimen, population or other use parameter not mentioned in the approved
labeling” of a drug or device.68 While off-label use of drugs has long been
authorized by the FDA, Congress more recently extended the same
endorsement of off-label use to devices when it passed the Food and Drug
Administration Modernization Act (“FDAMA”) in 1997.69 The FDAMA
states that the Act must not “limit or interfere with the authority of a health
care practitioner to prescribe or administer any legally marketed device to a
patient for any condition or disease within a legitimate health care
practitioner-patient relationship.”70 FDA maintains this general policy of
non-interference with the practice of medicine because “off-label uses or
treatment regimens may be important therapeutic options and may even
constitute a medically recognized standard of care.”71 Given the importance
of off-label uses in many circumstances, the agency merely constrains offlabel use by physicians by admonishing that physicians using “a product for
an indication not in the approved labeling . . . have the responsibility to be
well informed about the product, to base its use on firm scientific rationale
and on sound medical evidence, and to maintain records of the product’s use
and effects.”72 Essentially, the regulatory status of off-label use and
prescribing of drugs and devices represents a conscious choice by Congress
to prevent the FDA from regulating the physician-patient relationship,
limited only by Congressional recognition of “a patient’s right to seek civil
damages in the courts if there should be evidence of malpractice.”73 Given
such leeway in the practice of medicine, off-label prescribing by physicians
is widespread. An estimated 25% to 60% of all prescriptions are for
unapproved uses.74
Not only does the FDA endorse off-label uses, but the courts have also
affirmed the legitimacy of these activities. The Supreme Court has held that
the “ ‘off-label’ usage of medical devices is an accepted and necessary
corollary of the FDA’s mission to regulate in this area without directly
interfering with the practice of medicine.”75 Further, “no court has held that
a physician’s deviation from the officially approved labeling . . . is per se

	
  
http://www.fda.gov/regulatoryinformation/guidances/ucm126486.htm (last visited May
12, 2014).
68. Drug Maker to Pay $430 Million Fines, Civil Damages, FOOD & DRUG ADMIN.
(Aug. 2004), http://www.fda.gov/fdac/features/2004/404_wl.html (last visited May 12,
2014).
69. See 21 U.S.C. § 396 (2010).
70. Id.
71. “Off-label” and Investigational Use, supra note 67.
72. Id.
73. United States v. Evers, 453 F. Supp. 1141, 1148 (M.D. Ala. 1978).
74. Kim, supra note 4, at 11.
75. Buckman Co. v. Plaintiff’s Legal Comm., 531 U.S. 341, 349 (2001).
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negligence.”76 While a physician’s discretion to use an approved device for
an off-label use is not unlimited, and doctors do not “have sole and absolute
discretion in treating their patients,”77 the ability for physicians to pursue
off-label uses is typically quite broad.
Although physicians may use FDA approved drugs and devices for offlabel indications, pharmaceutical manufacturers are prohibited from
marketing or promoting these off-label uses.78 While the FDA is quite
active in the realm of enforcement of off-label promotion, the typical
circumstances surrounding cosmetic procedures make the ban on off-label
promotion less effective in this particular context.79 For example, the FDA
does not prohibit non-manufacturers from discussing the alleged benefits of
off-label uses of approved drugs and devices, whether or not there is
evidence to support the professed benefits, nor does it have jurisdiction to
regulate international marketing.80 Thus, information about cosmetic uses of
drugs and devices approved for other indications are often disseminated via
the advertisements of physicians who engage in these off-label cosmetic
procedures.81 Further, information about unapproved cosmetic uses may be
available on a manufacturer’s international website or on websites
maintained by entities that are unaffiliated with the manufacturer.82 In fact,
media and the Internet play a large role in the American obsession with
cosmetic surgery. When it comes to cosmetic procedures and innovations,
news of these treatments tend to “spread through mass marketing. The
Internet also spreads news and creates demand through list serves, web sites,
chat rooms, and spam.”83 The widespread availability of information
regarding off-label cosmetic uses of approved drugs and devices “constructs
cosmetic surgery as an option which is not only available to everyone, but
which bears the promise of an exalted life.”84 With a constant barrage of
promotions and promises, the allure of cosmetic procedures becomes too
irresistible for some to ignore.
At the same time that the mass media extol off-label uses of drugs and
devices for cosmetic purposes, data in the medical literature regarding the
safety and efficacy of these off-label procedures is often relatively
inconclusive. Specifically, researchers and clinicians have eagerly studied

	
  
76.
77.
78.
79.
80.
81.
82.
83.
84.

Kim, supra note 4, at 11.
Cabiroy v. Scipione, 767 A.2d 1078, 1083 (Pa. Super. Ct. 2001).
Kim, supra note 4, at 12.
Id. at 14.
Id.
Id.
Id. at 35-37.
Kim, supra note 4, at 7.
Id.
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the effects of liquid silicone in soft tissue alteration.85 Research has led to
the development of a method of administration known as the microdroplet
serial puncture technique, in which small amounts of liquid silicone are
inserted into the skin at 2-10 mm intervals.86 On the one hand, the American
Society for Dermatologic Surgery (“ASDS”), which has issued guidelines
regarding an array of injectable fillers, deems liquid injectable silicone
administered by the microdroplet serial puncture technique to be a safe and
efficacious material for permanent intra- and subdermal implantation within
the human body.87 Physicians and researchers in this camp maintain that the
overall cosmetic benefits of liquid silicone injections, and the fact that it
permanently remains in the body once injected, outweigh the risks of
migration and immune reaction.88 Notably, many clinicians prefer liquid
silicone to other popular fillers because it can be permanently implanted
underneath the skin, unlike collagen, fat, and Botox.89 For example,
injectable hyaluronic acid, including products such as Restylane and
Juvederm that are FDA-approved for injection of moderate to severe facial
wrinkles around the nose and mouth, is only a temporary filler, as the
substance is metabolized into carbon dioxide and water and eliminated via
the lymphatics and eventually the liver.90
Liquid silicone’s permanence can also be the source of its potential for
problems, including the risk of drift, as it cannot be removed once injected.91
Many physicians, however, maintain that the problems that plagued silicone
in the past can now be attributed to improper technique or using an
adulterated or impure formulation. Using silicone in too great a volume, for
example, can cause migration; adulterated formulations can lead to ulcers
and redness.92 Thus, the clinicians that support the use of liquid silicone
injections conclude that any possible issues associated with the permanence
of liquid silicone, as compared with other injectables, can be remedied with
proper attention to administration technique. These researchers caution that,
as with any filler, injection using the wrong amount, wrong material, or by
the wrong practitioner could result in adverse outcomes, such as swelling,
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beading, and discoloration.93 Thus, the ASDS notes that “judicious use of
[liquid injectable silicone] requires an appreciation of normal facial anatomy
and the changes that occur with aging and illness,” and suggests that
practitioners who perform liquid silicone injections have completed
residency training in a specialty where such information is taught, such as
dermatology or plastic surgery.94
On the other hand, some clinicians argue that liquid silicone injections
should be absolutely contraindicated in certain circumstances, including
injection into the breasts or horizontal facial creases, or only approached
with an abundance of caution in other scenarios, such as in patients with
chronic inflammatory disease or an active infection near the proposed
injection site.95 Given the controversy surrounding liquid silicone, the
American Society for Aesthetic Plastic Surgery (“ASAPS”) states that
silicone injections for cosmetic purposes should not be used except in the
context of a legitimately approved clinical trial.96 A plastic surgeon, in
recent media coverage about the increasing use of liquid silicone as a facial
filler, stated that liquid silicone appears to do a better job on facial lines as
far as plastic surgeons presently know, but noted a dearth of research
examining the long-term effects and results of these procedures up to 15
years following injection.97 Until more concrete research is obtained, he
urged physicians to err on the side of caution and avoid procedures
involving liquid silicone.98 In the face of these uncertainties, physicians
must use their best judgment to determine which FDA approved drugs or
devices his or her patient should receive in light of the information contained
in the product’s labeling and other available scientific data.99
These scientific disagreements remain unsettled, despite the fact that a
liquid silicone product known as SilSkin was granted an IDE in the early
2000s by the FDA for clinical study of cosmetic improvement of wrinkles
and depressions.100 SilSkin is the only liquid silicone product that has ever
been cleared by the FDA for cosmetic clinical trials.101 Its manufacturer,
Richard-James, Inc., was able to convince the FDA to allow clinical trials to
proceed in part because it presented the agency with results from autopsies
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of silicone users where material injected years earlier had not drifted.102
Information available near the time that FDA approved this IDE indicated
that the Phase II trials would involve 150 patients, followed for one year
while receiving SilSkin injections on one side of the face and collagen on the
other.103 Despite any original optimism surrounding these trials on the part
of the manufacturer and physicians, legal issues with SilSkin’s manufacturer
have prevented Phase III trials from commencing and producing meaningful
results.104 In addition to these FDA-sanctioned clinical trials, a new round
of studies involving the injection of Silikon 1000 into nasolabial folds of
HIV patients to treat HIV-related lipoatrophy have emerged.105 Some
physicians and researchers believe that these new trials, because they are
more rigorously designed than previous studies, will finally “provide
objective information regarding outcomes following the use of standardized
small volumes of medical grade silicone.”106
Although it remains a hypothetical question, it is important to consider the
implications if the FDA were to approve a liquid silicone product for
cosmetic uses. FDA approval can trigger the requirement for manufacturers
to engage in various forms of postmarket surveillance. Under Section 522,
the FDA may order the manufacturer of a Class II or Class III device to
conduct postmarket surveillance if the failure of the device would be
“reasonably likely to have serious adverse health consequences” or if it is
intended to be implanted in the body for more than one year.107 Arguably,
the possibility of silicone migration in the body after injection under the skin
could be reasonably likely to have serious adverse health impacts. Further,
as a permanent filler, injected liquid silicone would be implanted in the body
for more than one year. Thus, FDA approval of a liquid silicone device
could trigger helpful postmarket surveillance activities that would enhance
monitoring of cosmetic procedures involving liquid silicone.
FDA regulations define this type of surveillance as “the active, systematic,
scientifically valid collection, analysis, and interpretation of data or other
information about a marketed device.”108
Mandatory postmarket
surveillance stemming from FDA-approval of a cosmetic indication of a
liquid silicone device would be a great improvement to the currently weak
system of tracking and monitoring liquid silicone injections. Currently, the
FDA does not track adverse events associated with cosmetic liquid silicone
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injections.
The CDC’s Morbidity and Mortality Weekly Report
(“MMWR”), consisting of data gathered from voluntary reporting by state
health departments, contains only three mentions of liquid silicone
injections.109 The report, dating back to 2007, warns of acute renal failure
associated with silicone injections performed by unlicensed practitioners.110
Thus, at the very least, approval of a liquid silicone product for cosmetic
enhancement would be beneficial in remedying the dearth of available
adverse event reporting now available.
C. Illegal Liquid Silicone Injections
Between 1997 and 2011, the total number of minimally invasive cosmetic
procedures, including injectables, performed in the United States increased
by nearly 200%.111 As detailed above, some of these cosmetic procedures
involving the injection of liquid silicone are legal. This occurs when
physicians use approved liquid silicone products for unapproved off-label
cosmetic purposes. Unfortunately, however, the instances of illegal
cosmetic injections of liquid silicone (or other fluids falsely claimed to be
liquid silicone) are becoming increasingly widespread. Illegal liquid
silicone injections occur when individuals obtain injections at the hands of
unlicensed professionals, or when individuals are given injections of
adulterated or industrial-grade liquid silicone products.112 Individuals are
primarily drawn to the cosmetic procedure black market by the promise of
significant cost savings; while it costs roughly $5,000—7,000 to receive a
buttocks lift or implants at a legal clinic, illegal buttocks injections may cost
as little as $250.113 While cosmetic surgery bargain shopping may save
money upfront, “the price to fix a mistake could cost [these individuals]
everything,” including their health and their lives.114
So-called “bootleg” liquid silicone is readily available, and may be
purchased at local home improvement stores or gas stations. Typically, this
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adulterated liquid silicone is industrial-grade, and is often mixed with
various impurities.115 Such impurities may include floor products, sealers,
motor oil, and paraffin.116 This adulterated silicone fluid is then injected,
often by individuals with no training or experience, into “cheekbones,
eyebrow bridge, forehead, chin, lips, breasts, pectoral area, armpits,
buttocks, penis, thighs, hands, and hips.”117 When silicone injections are
performed in this illicit and clandestine manner, individuals who receive
injections are often deprived of the opportunity to receive various screening
and assessment evaluations that a licensed healthcare provider would
typically conduct. These assessments may include an initial consultation by
a physician, blood testing for allergic reactions or contraindications, risk and
benefit assessment, patient education, or social and psychological
evaluations.118 Further, illicit liquid silicone injections too often involve the
injection of excessive volumes of silicone, poor technique on the part of
unskilled operators, and unhygienic conditions surrounding the procedure.119
A rash of deaths and injuries related to illicit liquid silicone injections have
been highlighted in the media in recent years; frequently death occurs
following a silicone pulmonary embolism, in which injected silicone travels
through the blood stream to the lungs.120
Neither the Centers for Disease Control (“CDC”) or the FDA maintain
data regarding injuries or deaths caused by illicit cosmetic injections, nor
does the public health literature contain substantive information regarding
the health implications of illegal liquid silicone injections.121 Research
regarding silicone injections has been most thorough in the context of the
transgender population. While other population subgroups including drag
queens, heterosexual women, and gay men currently participate in the illicit
market for silicone injections, these injections were first adopted widely in
the transgender community.122 Ruby Corado, one transgender woman
profiled in a recent news article, began injecting liquid silicone into her
buttocks, hips, and thighs in the late 1990s.123 During a beauty pageant at
her transgender club, a man took the stage to pitch silicone injections he
offered at a local hotel. The man claimed he was a nurse in Cuba and
worked with plastic surgeons, and Corado became hooked on the
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procedures. Nearly two decades later, however, Corado told reporters that
her “silicone hips have migrated to her thighs and her once-juicy booty is
hard and sensitive to the touch. Her immune system is weak, but she knows
her symptoms could be much worse.”124 Such hotel room procedures have
been common in the transgender community, as has the phenomenon of
dangerous “pumping parties.”125 At a typical pumping party, groups of
transgender individuals receive silicone injections from an unlicensed,
untrained person using non-medical silicone. These parties may occur at a
beauty parlor, at a private home, or even in a warehouse. According to one
doctor who specializes in transgender health services, economically
disadvantaged and vulnerable transgendered individuals are particularly
willing to forego safety costs in the pursuit of beauty because being shapely
and beautiful is “a self-esteem builder for people who are feeling rejected by
their families and communities.”126 Given the fact that illicit liquid silicone
injections and pumping parties have been popular within the transgender
community for quite some time, some data regarding the prevalence of these
practices among transgender individuals has been amassed. Research has
found “illicit injection silicone rates among transwomen to be 25% in
Washington, DC; 30% in New York City and Chicago; and 33% in Los
Angeles.”127 Moreover, the National Coalition for LGBT Health has
confirmed this startling prevalence, reporting that the injection of industrial
silicone is so widespread among transpersons that it is one of 13 high
priority health issues affecting the population.128
In recent years, however, pumping parties have gained popularity amongst
other population subgroups outside of the transgender community. For
example, many young, African-American women are now pursuing silicone
injections to amplify their curves. As one news article put it: “[h]aving once
shied away from and even denounced plastic surgery, black women are
embracing it now more than ever.”129 Pop culture has fueled the desire for a
fuller behind, and society has gone from accepting curves to obsessing over
large bottoms.130 In fact, in 2011, racial and ethnic minorities received 21%
of all cosmetic procedures: Hispanics, 8%; African-Americans, 7%; Asians,
5%; and other non-Caucasians, 1%. 131 In addition to the growing popularity
among African-American women, Hispanic women are also increasingly
turning to illicit liquid silicone injections.
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Indeed, South Florida “has become the nation’s capital of black market
beauty treatments.”132 Many illegal beauty treatments in this region are
offered by immigrant practitioners who live in the state, or by foreign health
care practitioners who fly to Florida to treat clients.133 Some have noted that
“Miami offers perfect-storm conditions for cosmetic crime, [as] it’s a nexus
of vanity, greed, corruption, warm weather, beautiful men and women
walking around all the time wearing as little clothing as possible and
unsophisticated immigrants trying to compete with them.”134 The social
fabric of Miami and its large immigrant populations can help foster
underground cosmetic procedure providers. Women within these tightly
knit immigrant communities may be more likely to trust the
recommendations of friends and family who have been treated by various
black market practitioners.135 For example, one Florida woman named
Angelina McCabe used local beauty salons to network and get referrals for
her silicone lip injection business. When McCabe was ultimately reported
by a victim, it came to light that some clients had contracted herpes from her
unsanitary syringes, which were found in her medical bag used and covered
with dog hair.136
IV. REGULATION OF AND ENFORCEMENT AGAINST ILLICIT LIQUID SILICONE
INJECTIONS
Given the increasing prevalence of illicit liquid silicone injections, as well
as the significant health risks associated with these procedures, it is critical
that both the federal government and state and local governments actively
enforce laws and regulations designed to curb such practices. At the federal
level, this enforcement jurisdiction rests primarily with the FDA. Although
physicians may lawfully use an approved liquid silicone product for an offlabel cosmetic use, no person may administer unapproved, adulterated liquid
silicone devices in any manner. The 1976 Medical Device Amendments to
the FDCA established three regulatory classes for medical devices based on
risk and the degree of control necessary to ensure safety and effectiveness.
Class III devices are the most stringently regulated, and Section 515 of the
FDCA requires all Class III medical devices to obtain an approved PMA.137
A Class III device that fails to meet PMA requirements is considered to be
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adulterated under Section 501(f) of the act and cannot be marketed.138
Silikon 1000 and Adatosil 5000, the two FDA-approved silicone oil
products, are Class III devices that submitted successful PMA applications
to the FDA in 1997 and 1994, respectively.139
The FDA continues to regulate medical devices once they are successfully
approved for marketing in interstate commerce by controlling the contents of
the product’s labeling. First, the FDA demands that the label of a medical
device must not be false or misleading in any particular.140 Therefore, if a
manufacturer falsely held out a silicone oil product for sale to physicians as
Silikon 1000 or Adatosil 5000, the product would be misbranded under the
FDCA. Second, a medical device’s label must provide adequate directions
for use.141 The label must therefore include directions related to the FDAapproved use of Silikon 1000 and Adatosil 5000 for the treatment of retinal
detachment. Failure to include these adequate directions for use on a label
misbrands the device under the FDCA.142 Furthermore, any addition to the
device’s labeling that would suggest that the liquid silicone product was
FDA-approved for a cosmetic or other indication would cause the device to
be adulterated under the FDCA. This is because Section 501(f)(1)(B) of the
Act, requiring pre-market approval for Class III devices, considers claims
that exceed the scope of a previously FDA-approved indication to adulterate
the device.143
“Federal regulation of medical products is grounded in the introduction of
devices in interstate commerce for commercial distribution, not use by
physicians.”144 In regards to medical devices, “the doctrine implies that a
licensed physician may use any legally marketed device for any indication
that he or she feels is appropriate.”145 This concept forms the basis for the
“practice of medicine” doctrine, which maintains that FDA lacks authority
under the FDCA to regulate the patient treatment decisions of licensed
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physicians.146 Thus, federal regulatory efforts are directed primarily at
device marketing by manufacturers, not device use by physicians.147 It is
quite possible, therefore, that a state-licensed physician may enjoy wide
latitude in treatment use of a medical device that the physician himself or
herself has modified, even if the same modification of an FDA-approved
device would be sufficient to trigger 501(f)(1)(B) of the Act where a
manufacturer made such changes.148
Therefore, it falls entirely on the state to appropriately regulate the
practice of medicine. The Supreme Court has long recognized that the
state’s police powers justify their regulation of the practice of medicine and
allow the state to license health care professionals.149 Thus, states maintain
statutes that regulate various fields of the medical profession and define the
scope of practice in which health practitioners may engage.150 These
statutes typically define the authorized practice of medicine and also define
and punish unauthorized practice.151 Generally, the unauthorized practice of
medicine occurs in one of two scenarios.152 First, when a person without a
medical license performs activities that fall under the definition of the
practice of medicine or holds himself or herself out as a licensee.153 Second,
when an otherwise licensed practitioner performs activities outside the scope
of his or her particular medical field.154 Beyond state medical board
oversight, state law also regulates the practice of medicine through private
suits for malpractice.155 Theoretically, “physicians who practice in a manner
that is unsafe or ineffective can face disciplinary action and civil liability.
But, in reality, state medical boards infrequently discipline physicians for
improper practice.”156 In addition, it has been found that the threat of
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potential malpractice suits also does not seem to deter the proliferation of
questionable medical services.157
While “state statutory definitions [of the practice of medicine] vary
tremendously, most of them include diagnosis, prescribing, and surgical
interventions among the central attributes of medical practice.”158 In
Florida, Section 456.065 of Chapter 456 of the Florida Statutes regulates the
unlicensed practice of a health care profession.159 The statute prohibits “the
unlicensed practice of a health care profession or the performance or
delivery of medical or health care services to patients in this state without a
valid, active license to practice that profession, regardless of the means of
the performance or delivery of such services.”160 Penalties for the
unlicensed practice of a health care profession in Florida include: (1)
Issuance of a cease and desist letter when the Department has probable cause
to believe an unlicensed person has violated the statute or that a person has
aided and abetted the unlicensed practice of a profession by employing an
unlicensed person; (2) An administrative penalty not to exceed $5,000 per
incident; (3) A civil penalty of no less than $500 and no more than $5,000
for each offense; and (4) Criminal penalties.161
While the existence of state statutory provisions defining the unlicensed
practice of medicine is important, it is critical that these laws be effectively
and efficiently enforced in order to deter and punish individuals who seek to
perform unlawful cosmetic injections. “Florida has a dedicated investigative
arm for unlicensed activity.”162 The Division of Medical Quality Assurance
(“MQA”) regulates 37 types of facilities and 43 health care professions.163
The MQA serves a variety of functions, including credentialing licensing
applicants, inspecting facilities, and decreasing unlicensed activity. 164 The
MQA also maintains a separate unlicensed activity unit (“ULA”); in
cooperation with law enforcement and state attorney generals, the ULA
seeks to prosecute unlicensed practitioners.165 In order to identify these bad
actors, all complaints are routed centrally through the Florida Department of
Health.166 If, upon preliminary review, the complaint is deemed legally
sufficient, it is forwarded to a ULA investigator located in close geographic
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proximity to the complaint location.167 Local ULA investigators undertake
activities such as interviewing the complainant and witnesses, gathering
documents, and conducting surveillance in order to determine whether or not
the allegations contained in the complaint are supported.168 These ULA
investigations are designed to develop the probable cause law enforcement
entities require to file criminal charges. Fees contributed by licensees fund
the ULA; all licensees must pay a $5 special fee for both initial licensing and
each subsequent renewal.169 According to the program’s fourth quarter 2012
Quarterly Performance Report, 99 complaints were filed with the ULA, 76
investigations were completed, 52 cases were referred to law enforcement,
and 16 arrests resulted from ULA investigations.170
California uses a similar vertical prosecution model to enforce its laws
related to the unlicensed practice of medicine.171 First, consumers file a
complaint with the Medical Board of California.172 This complaint is
directed to the Board’s Central Complaint Unit (“CCU”). Then, a Deputy
Attorney General and the Complaint Unit Analyst make a determination
regarding whether or not immediate investigation or some other government
action is warranted by the complaint.173 If an investigation is warranted, the
CCU forwards relevant information to the District Office in closest
proximity to where the alleged acts of unlicensed practice occurred.174 At
this stage, the case is assigned to an investigator and a Deputy Attorney
General.175 This team will work together on the case until it is either: (1)
closed; (2) referred for disciplinary action; or (3) referred for other action,
including a criminal prosecution.176 If a criminal prosecution is sought, the
team forwards the case file to a district attorney in the relevant
jurisdiction.177
In addition to unlicensed practice statutes, some states include specific
language regarding the administration of cosmetic injections and other
cosmetic procedures in laws, regulations, and policies that delineate the
scope of practice of various health care professions.178 In particular, many
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states have issued guidelines regarding which medical professionals are
permitted to inject patients with Botox and other dermal fillers.179 Although
these provisions do not explicitly mention liquid silicone injections, states
that have restricted cosmetic injections of dermal fillers in some manner
include: Alabama, California, Colorado, Florida, Georgia, Kentucky,
Maryland, Mississippi, Missouri, New Jersey, New Mexico, Ohio,
Oklahoma, Oregon, Rhode Island, South Carolina, and South Dakota.180
These laws and policies, however, vary widely from state to state.181
Alabama, New Jersey, and South Carolina, for example, restrict cosmetic
injections to licensed physicians.182 In South Carolina, however, this
restriction is merely embodied in a policy issued by the state’s Board of
Medical Examiners; as such, disciplinary action may be the only likely result
of its violation.183 The policy, issued during the Board’s 2002 board
meeting, states that “the revision, destruction, or other structural alteration of
human tissue using an injection of drugs is surgery. Botox injections should
be performed only by individuals licensed to practice medicine and perform
surgical services.”184
Many of the other states listed simply provide guidelines for procedures
that must or should be followed when a physician delegates the
administration of dermal fillers to nurses, physician’s assistants, or other
allied health professionals. In Maryland, for example, a cosmetic medical
procedure can be delegated to a physician’s assistant or to another health
care professional licensed under the Maryland code whose licensing board
states that such procedure falls within the scope of that licensee’s practice.185
Finally, the status of some state laws and policies in this area are conflicting
or confused. In Colorado, for example, a broad regulation provides
restrictions and guidance related to delegation of medical aesthetic services
such as Botox and other injections,186 but information available from the
state’s Board of Barbering and Cosmetology states that “[c]ollagen, silicone,
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or Botox injections are invasive procedures and may only be performed by
licensed physicians.”187
Relatively few states currently maintain laws specifically banning
cosmetic uses of liquid silicone. In California, it is a misdemeanor to
knowingly prescribe, dispense, administer, or furnish any liquid silicone
substance for the purpose of injection into a human breast or mammary.188
Notably, the breadth of this statute is restricted in two primary ways: first,
this law specifies an intent requirement of “knowledge,” and second, only
injection of liquid silicone into the breast or mammary is specifically
outlawed. In Nevada, with the exception of use for the treatment of retinal
detachment, it is unlawful for a person to inject any liquid silicone substance
into the body or to sell any liquid silicone substance for the purpose of
injection into the human body. Violation of this provision is a category D
felony. This law is much stricter than the California statute. The plain
language of the Nevada statute implies that it is unlawful for even a
physician to pursue cosmetic injections of liquid silicone as an off-label
use.189 While the California and Nevada statutes are the only state
regulations currently in force, Rhode Island has proposed a law that would
function in a similar manner to Nevada’s law. The proposed statute states
that medical licenses may be denied or revoked if a health professional
“[performs, assists, or advises] in the injection of any liquid silicone
substance into the human body.”190 While it is promising that a few state
legislatures have focused specifically on the dangers of cosmetic liquid
silicone injections, it is simultaneously disheartening that these statutes are
in effect in so few jurisdictions.
V. THE WAY FORWARD: THE MOST PROMISING LEGAL TACTICS FOR
CONTROLLING LIQUID SILICONE INJECTIONS
The rampant use of liquid silicone in cosmetic procedures, despite an
overwhelming lack of scientific data and information demonstrating safety
and concerns regarding serious health risks, triggers cause for concern and
increased attention to the implications of its widespread use. In addition, the
growing prevalence of unlicensed practitioners hawking cheap but unsafe,
even lethal, illicit liquid silicone injections provides a reason to focus not
only on its used by licensed professionals, but also on the market for liquid
silicone in general. This section outlines how the federal government could
address these issues, but ultimately explains that federal regulation in this
area has traditionally been weak, and will not likely be augmented to cover
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liquid silicone. Thus, in place of enhanced federal enforcement, this section
concludes with state-level regulatory and enforcement tactics aimed at both
licensed healthcare professionals and unlicensed practitioners.
A. Federal Enforcement Is Unreliable and Likely to Be Weak or NonExistent
As discussed in parts II and III supra, FDA enforcement against off-label
cosmetic uses of liquid silicone has historically been weak. Although FDA
has never approved a liquid silicone device for cosmetic uses, the agency
does not generally interfere with off-label procedures involving these
devices. While it is true that the FDA did enter consent decrees of
permanent injunction against physicians such as Dr. Norman Orentreich,
who violated liquid silicone IDE protocols in the early 1990s, these federal
enforcement efforts were relatively weak.191 Further, these injunctions were
instigated because physicians were purposely violating IDE protocols
specifying that liquid silicone trials were not to involve cosmetic uses.192
Thus, there is reason to assume that the FDA would be even more hesitant to
pursue action against physicians improperly using a device such as SilSkin
in a clinical trial, as that product did receive an IDE for cosmetic testing.
Despite the FDA’s acceptance of off-label prescribing of approved drugs,
it is theoretically possible that Congress could carve out an exception for
liquid silicone. Congress could enact a statute that directs FDA to curtail
off-label cosmetic uses of approved liquid silicone by physicians. It is
difficult to imagine that this sort of legislation would be politically feasible;
the medical community is a powerful constituency in any state, and it
typically decries FDA regulation of the practice of medicine.193 It could be
argued, however, that, when it comes to off-label medical uses of silicone
fluid specifically, the informal moral and social controls that serve to protect
patients do not always work. Due to a convergence of factors including
societal pressure to attain beauty standards, the lucrative nature of the
cosmetic surgery and procedures industry, and the still largely unknown
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long-term safety and efficacy profile of injectable liquid silicone, a stronger
regulatory stance is needed for this particular device. Indeed, this sort of
action would not be entirely unprecedented. Congress has expressly
prohibited all off-label use for one drug, human growth hormone (“HGH”).
Section 3303(e)(1) of the FDCA makes it a criminal offense for a physician
to distribute HGH for any use other than the FDA-approved labeled use.194
B. State-Level Solutions Can Produce Immediate Results
As noted above, there are significant barriers standing in the way of
effective federal enforcement against off-label cosmetic procedures
involving liquid silicone. As such, states should be encouraged to take the
lead in regulating the off-label and illicit cosmetic uses of liquid silicone.
The following section outlines state-level enforcement tactics geared
towards both physicians and unauthorized practitioners that promise to be
more immediately feasible and practicable than federal solutions.
1. State-Level Enforcement Tactics Targeting Physicians and the
Healthcare Community
One of the most promising avenues for state-level efforts to reduce the
number of dangerous cosmetic procedures involving liquid silicone
performed is encouraging state medical boards to revisit and amend their
practice of medicine and scope of practice laws. While the unlicensed
practice of medicine tends to attract more negative publicity and media
attention, the fact that nearly all U.S. jurisdictions permit any physician with
a medical degree and license to perform cosmetic procedures, regardless of
his or her level of formal or specialized training in any relevant field, should
be deeply troubling, as well.195 Although approximately 80 percent of
licensed physicians receive specialty certification from one of 24 boards
approved by the American Board of Medical Specialties, a process requiring
at least three years of residency in the chosen concentration area and
extensive oral and written exams, there are no laws in the United States that
require doctors to practice only within the specialty fields in which they
were trained.196 Further, only Texas, California, Louisiana, and Florida
require physicians, in their advertising, to be specific about which specialty
board certifications they have; elsewhere, the vague accolade, “board-
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certified,” suffices.197 Because doctors do not have to report to any
oversight authority that they are practicing outside their specialty, there are
no figures indicating exactly how many physicians are doing so.
Nevertheless, media reports of patients being seriously injured by cosmetic
surgery performed by unqualified doctors abound, indicating that the
unregulated nature of cosmetic surgery is cause for concern.198
Some physicians who aspire to be cosmetic surgeons attend weekend-long
continuing medical education courses, where they learn to perform filler
injections and liposuction by physicians who themselves are not certified by
the American Board of Plastic Surgery.199 Often, these newly-minted
cosmetic surgeons claim certification by Boards that are not endorsed by the
American Board of Medical Specialties, and which have lower standards and
are far less rigorous.200
It is precisely these issues that spurred Puerto Rico’s Board of Medical
Examiners to enact the nation’s first regulation limiting the practice of
cosmetic medicine to particular classes of medical specialists in 2005.201
The plaintiff who challenged this regulation was a physician with board
certification in obstetrics and gynecology that, while practicing, shifted his
focus to performing liposuctions and breast implantations almost
exclusively.202 The Board had come to recognize that this “plaintiff’s
odyssey was not unique,” and noticed that “the majority of professionals that
market[ed] their services as ‘aesthetic medicine’ [were], in reality, general
physicians that [had] no formal training . . . in the skills that are purportedly
offered to the public.”203 Thus, the Board deemed it the “illegal practice of
medicine [when] any person . . . advertises, practices or purports to practice
the procedures that fall under the competence of dermatologists or plastic
surgeons without possessing the certification in the corresponding
specialty.”204 The First Circuit Court of Appeals upheld this regulation in
2011.205 More states should follow the lead of Puerto Rico and limit the
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practice of cosmetic surgery to physicians who have been certified by the
American Board of Plastic Surgery or the American Board of Dermatology.
These sorts of restrictions may be a necessary step, as there is some evidence
that, given how lucrative aesthetic medicine can be for practitioners, doctors
who provide these types of services may be less likely to self-regulate in a
manner that is sufficiently stringent.206
States can also make enhanced efforts to restrict off-label cosmetic uses of
liquid silicone in a manner the FDA cannot or will not, given its
commitment to giving physicians a wide berth when it comes to off-label
prescribing or use of FDA-approved drugs. As discussed in part IV supra,
some states have enacted statutes that make it a criminal offense to inject
liquid silicone into a person’s body. Specifically, the plain language of
Nevada’s law prohibits all medical uses, cosmetic or otherwise, for liquid
silicone products beyond its narrow approved indication for treating retinal
detachment.207 More states should consider adopting similar statutes, which
would deter cosmetic uses for liquid silicone by licensed physicians and
unlicensed practitioners alike.
2. State-Level Enforcement Tactics Targeting Unlicensed
Practitioners and Illicit Uses for Liquid Silicone Products
States may be hesitant to interfere with the practice of medicine and a
physician’s reasoned medical discretion in using approved liquid silicone
products for off-label uses. If this is the case, states can focus primarily on
eradicating illegal and black market uses of liquid silicone and silicone oil.
For example, states can enact laws that regulate the sale of commercial grade
silicone, often used in illicit silicone injections by unlicensed practitioners.
A parallel area of state legislation that states can use as a model for such
laws can be imported from the regulation of the dispensation and distribution
of various legal substances that can be used illicitly as inhalants. For
example, Ohio Law prohibits dispensing nitrous oxide to any person under
the age of 21, or to a person over the age of 21 if the person who dispenses
the substance knows or has reason to believe that person over the age of 21
will use the nitrous oxide as an intoxicant.208 The law also requires those
who dispense or distribute nitrous oxide cartridges to comply with recordkeeping and labeling requirements.209 Anyone who dispenses nitrous oxide
must record each transaction on a card, which must include the purchaser’s
signature and residence address, as well as information stating that the
nitrous oxide cartridges are to be used only for purposes of preparing food,
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and that inhalation of nitrous oxide can have dangerous health effects.210
Further, the law requires each cartridge of nitrous oxide dispensed or
distributed within the state to bear the following warning label: “Nitrous
oxide cartridges are to be used only for purposes of preparing food. Nitrous
oxide cartridges may not be sold to persons under age twenty-one. Do not
inhale contents. Misuse can be dangerous to your health.”211 Similarly,
states could apply these types of regulations to liquid silicone products,
making it more difficult to purchase these products for illicit uses, and
making it easier for the state to track those who do purchase the product.
Another key area for state action targeting illicit uses of liquid silicone
products by unlicensed practitioners rests with state attorneys general
offices. As discussed in section IV, supra, Florida’s ULA has achieved a
strong track record in deterring and punishing individuals who offer and
conduct dangerous cosmetic procedures within the state.212 There are
several avenues that can be used to encourage a state attorneys general office
to focus enforcement activities in a certain area, such as illicit injections of
liquid silicone products. First, licensed practitioner groups, such as state
medical associations, could lobby the state to take increased steps to root out
bad actors from within the industry that provide off-label cosmetic injections
of liquid silicone for profits, despite a lack of scientific knowledge regarding
the long-term effects and health consequences of these procedures. In this
way, the state can serve as enforcement support in an industry’s attempt to
police itself. Second, state attorney general offices can be alerted to the need
for increased attention to this issue through consumer complaints. Citizens
who have been the victim of dangerous cosmetic procedures involving liquid
silicone should be encouraged to report their ordeals to the state; awareness
campaigns could help decrease the embarrassment or stigma associated with
doing so. Finally, because states often obtain their legislative and
enforcement priorities from cases or issues on the horizon in other states,
and often learn of national issues from contacts at meetings of organizations
like the National Association of Attorneys General (“NAAG”), those
interested in promoting more widespread enforcement efforts against illicit
liquid silicone injections can attempt to spread awareness of the dangers of
these procedures by giving seminars at the meetings and conferences of
these associations.213 If states do begin to embark on greater enforcement
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efforts in this area, it could be helpful for neighboring jurisdictions to band
together and create a reporting network or database, which would store data
and information related to the results of these various tasks forces and
investigatory efforts. Given enough traction and progress, the information
contained in this database could help public health stakeholders build a case
for eventual federal regulation or oversight to curb a major nationwide
health issue.
VI. CONCLUSION
Although the FDA has historically focused some regulatory scrutiny on
the cosmetic uses of liquid silicone products, the scope of such efforts has
been limited, and has not resulted in effective deterrence. While the science
regarding the safety and long-term effects of cosmetic liquid silicone
injections remains inconclusive, and the illicit uses of liquid silicone on
vulnerable populations by unlicensed practitioners grows increasingly more
prevalent, it is important to remain cautious, and to keep close watch on
these procedures. It is critical, therefore, that states take up the federal slack
in this area. States can accomplish this by restricting the use and sale of
liquid silicone products by physicians and unlicensed practitioners alike, and
also by prioritizing enforcement activities on deterring illicit liquid silicone
injections, which are arguably the most lethal, and most hidden, practices
involving this substance.
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